Sage Therapeutics pulls brakes on Alzheimer’s drug after failed trial … CDC: 35% flu shot efficacy in South America could be similar for US … Study spots brain protein waste-disposal mechanism
Also in the News for Tuesday, June 11, 2024
By
Kimberly Marselas
Jun 10, 2024
Cuomo scheduled for congressional questioning on COVID nursing home deaths … California contemplates further limits on private equity transactions … LTC insurance policy holders find new obstacles...
Report: Monoclonal antibodies for dementia lack clear benefits, show risks
By
Kristen Fischer
Jan 23, 2024
Even though amyloid-reducing monoclonal antibodies (MABs) are on the market and some research shows they may treat Alzheimer’s disease and dementia, a new research review found there aren’t clear benefits...
Also in the News for Tuesday, Sept. 19
By
Kimberly Marselas
Sep 19, 2023
HHS finalizes rule easing seniors’ access to Medicare Savings Program … Fitch: More bad news ahead for life plan communities … Will new COVID vaccines get to those who need them most? … Lumbar...
Trial for Alzheimer’s drug combo looks encouraging so far
By
Kristen Fischer
Sep 11, 2023
A trial evaluating the combination therapy of a drug and an antioxidant shows promise in treating Alzheimer’s disease, according to a new report.
Also in the News for Tuesday, Aug. 15
By
Kimberly Marselas
Aug 15, 2023
Older, discharged COVID patients have double the risk of dying vs. flu patients: study … Private insurers denying coverage for new Alzheimer’s drugs … After turning away from skilled nursing, Invesque...
Also in the News for Friday, Aug. 4
By
Kimberly Marselas
Aug 04, 2023
CMS policy on new Alzheimer’s drugs restricts rural access: former senator … Bedbugs may spread MRSA: study … CIDRAP: Sporicidal disinfectants better against Candida Auris … Nearly 30 affected...
FDA panel says new data support ‘full’ approval of Alzheimer’s drug Leqembi
By
Alicia Lasek
Jun 12, 2023
New trial data for lecanemab (Leqembi) supports traditional, or “full” federal approval, the agency’s advisers said Friday. The decision is a step toward possible expanded patient access.
A first: FDA approves drug to treat agitation in Alzheimer’s dementia
By
Alicia Lasek
May 12, 2023
For the first time, the FDA has approved a drug to treat agitation related to Alzheimer’s disease dementia. Patient advocates are hailing the news, but prescribing the drug, an antipsychotic, may put...
Alzheimer’s drug donanemab finds late-stage trial success, safety concerns
By
Alicia Lasek
May 04, 2023
The experimental drug donanemab appears to halt the progression of Alzheimer’s disease and slow certain measures of clinical decline, new trial data show.